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Aim. Lebanon exhibits one of the highest prevalences of factor V-Leiden (FVL) in the world (14.4%). The aim of this study
is to evaluate the incidence of FVL mutation among Lebanese patients with lower extremity venous thrombosis. Material and
Methods. From January 2003 to January 2011, 283 consecutive Lebanese patients, diagnosed with deep venous thrombosis (DVT)
by duplex scan, were retrospectively reviewed. FVL mutation was tested among patients with conditions highly suggestive of
hypercoagulation states (65 patients). Results. FVL mutation was detected among 56.9% of patients, 68.6% of patients younger
than 50 years, and 43.4% of patients older than 50 years (P = 0.041). FVL mutation was commonly reported in young adults,
in patients with pregnancy, estrogen drugs, recurrent DVT, and resistance to anticoagulation. Conclusion. The high rate of FVL
mutation observed among Lebanese patients with venous thrombosis is related to the high prevalence of this mutation in the
Lebanese population. Thrombophilia screening should be tailored to accommodate a population’s risk factor. In countries with
highprevalenceofFVL,thismutationshouldbescreenedamongpatientsyoungerthan50yearsandpatientswithsituationshighly
suggestive of hypercoagulation states.
1.Introduction
The appropriate management of venous thrombosis requires
a thorough knowledge of diagnostic and treatment modal-
ities. However, an understanding of the underlying epi-
demiology and associated risk factors is equally essential.
Pathophysiology of venous thrombosis is multi-factorial
and involves environmental, acquired, and genetic factors.
Factor V R 506 Q-Leiden is the most frequent prothrom-
botic genetic abnormality leading to thrombophilia. The
prevalence rate of this mutation varies according to ethnic
and geographic distribution of the populations. The allele
mutation is high among Eastern Mediterranean populations
and extremely high among Lebanese population. The aim of
this study is to determine the incidence of factor V-Leiden
mutation among Lebanese patients with lower extremity
venous thrombosis and high risk situations for hypercoag-
ulation states and to discuss the reported results according
to epidemiologic and pathophysiologic publications in the
international literature.
2.MaterialandMethods
From January 2003 to January 2010, 283 consecutive
Lebanese patients (115 males and 168 females), diagnosed in
an academic tertiary-care center with lower extremity deep
venous thrombosis using color ﬂow duplex scan (Prosound
Alpha 7 ALOKA, Zug, Switzerland), were retrospectively
reviewed. Age varied between 21 to 96 years (mean: 64.9
years). Factor V-Leiden was screened among 65 of the
283 patients, presenting with speciﬁc conditions highly
suggestive of hypercoagulation states according to the guide-
lines proposed by the European Genetics Foundation, the
Cardiovascular Educational and Research Trust, the Interna-
tional Union of Angiology, and the Mediterranean League
on Thromboembolism [1]. These conditions were young
age, pregnancy, oral contraceptives and estroprogestative
drugs, spontaneous, extended and recurrent DVT, family
history, resistance to anticoagulation, long-haul air travel,
and constituted the inclusion criteria for testing FVL.2 Thrombosis
There was no exclusion criteria. Accordingly, FVL muta-
tion was tested in 37 young patients, in 9 pregnant patients,
in 5 patients using oral contraceptives or treated with hor-
mones, in 32 patients with spontaneous venous thrombosis,
in9patientswithextendedvenousthrombosis,in15patients
with recurrent venous thrombosis, in 11 patients with family
history of venous thromboembolism (VTE), in 4 patients
withresistancetoanticoagulants,andin2patientswithlong-
haul air travel. Fourteen patients presented with one of these
high risk conditions requiring FVL testing, 18 with two, 2
with three and 3 with four conditions.
Inherited prothrombotic risk factors including FVL,
prothrombin G 20210 A, factor V H 1299 R, MTHFR C
677 T, and MTHFR A 1298 C mutations were determined
using CVD strips according to the protocol supplied by the
manufacturer (CVD Strip Assays R, ViennaLab, Austria).
Plasma homocysteine level was also reported.
Patients were subdivided into 2 groups according to
age—A: younger than 50 years (35 patients) and B: older
than 50 years (30 patients).
A clinical research form was ﬁlled out with every patient,
by a retrospective evaluation of clinical presentation and
risk factors for venous thrombosis; data were entered and
analysed by SPSS Statistics (IBM Corporation, Somers, NY,
USA) software, version 13.0. A chi-square test was used to
correlate between dichotomous variables, and a Fisher exact
test was used in case of calculated values that were lower than
ﬁve.
3. Results
Factor V-Leiden was detected among 37 patients represent-
ing 56.9% of the tested patients. More than one clinical
risk factor was associated with a higher risk of positivity for
FVL (63% comparing to 44% for the other prothrombotic
genetic mutations). Five patients (7.7%) were carriers for
the homozygous form and thirty-two (49.2%) for the het-
erozygous form. Factor V-Leiden was isolated in 19 patients
and associated with prothrombin G 20210 A mutation in
4 patients and with other prothrombotic genetic mutations
in 14 patients (MTHFR C 677 T mutation: homozygote: 2,
heterozygote: 9, MTHFR A 1298 C mutation: heterozygote:
8, and V H 1299 R mutation: heterozygote: 1) (Table 1).
Plasma homocysteine level was increased in 8 patients. The
association with other genetic risks did not increase the
risk of recurrent DVT but was determinant of more severe
and extended forms of VTE. Factor V-Leiden was more
commonly reported in the younger age group 9 (group
A) comparing to the older age group (group B) (68.6%
comparing to 43.4%; P = 0.041).
FVL mutation was detected among 66.6% of pregnant
patients, 60% of patients using oral contraceptives or treated
with hormone therapy, 56.2% of patients with spontaneous
DVT, 55.5% with extended DVT, 66.6% of patients with
recurrent DVT, 45.4% of patients with family history of
venous thromboembolism, 100 % of patients with resistance
to anticoagulants and 50% of patients with long-haul air
travel (Table 2).
Table 1: Prothrombotic genetic mutations associated with FVL
mutation.
Prothrombotic genetic mutation Number of patients
Prothrombin G 20210 A 4
MTHFR C 677 T 11
MTHFR A 1298 C 8
V H 1299 R 1
Table 2: Conditions associated with FVL mutation.
High risk conditions
Patients
screened for
FVL mutation
Patients carriers for
FVL mutation
Young patients (A group) 35 24 (68.6%)
Pregnancy 9 6 (66.6%)
Estrogen treatment 5 3 (60%)
Spontaneous DVT 32 18 (56.2%)
Extended DVT 9 5 (55.5%)
Recurrent DVT 15 10 (66.6%)
Family history of VTE 11 5 (45.4%)
Resistance to anticoagulant 4 4 (100%)
Long-haul air travel 2 1 (50%)
4. Discussion
Resistance to activated protein C degradation caused by a
mutation in the factor V R 506 Q-Leiden is the most preva-
lent inherited cause of venous thrombosis. The prevalence
rate of factor V-Leiden in the general population varies
from 0% to 15% according to ethnicity and geographic
distribution [2, 3]. The allele mutation is low in African,
Asian,SouthEuropeanpopulations(1%–3%),relativelyhigh
in United States populations (5%) and high in Mediter-
ranean populations (13.6% in Syria, 12.3 % in Jordan, and
13.4% in Greece) [4, 5]. Lebanon exhibits one of the highest
frequencies of FVL mutation in the Eastern Mediterranean
and in the world with a prevalence of 14.4% in the general
population [6].
Among the inherited thrombophilias, factor V-Leiden
gene mutation is the most common predisposing factor,
accounting for 10% to 20% of VTE in large population
studies [7, 8]. Some authors suggest that this mutation
is present in up to 37% of patients with postthrombotic
syndrome [1]. The lifetime probability of symptomatic VTE
inpatientswithheterozygousFVLmutationisapproximately
10% [9]. The risk of VTE is increased 3- to 7-fold in
heterozygotes for FVL and 50- to 100-fold in homozygotes
[8, 9].
The prevalence of FVL mutation among patients with
venous thrombosis varies considerably according to the
origin of the reported study. It is extremely low in Singapore
(0.26%), low in Spain and in the United States (8.3% and
9%, resp.), relatively high in the United Kingdom, Greece,
and Tunisia (15.6%, 16.8%, and 20.3%, resp.) and high in
Italy (24.3%) [10–15]. This prevalence signiﬁcantly increases
among adults younger than 50 years of age in DenmarkThrombosis 3
(32.7%) and Czech Republic (40%), but remains very low in
India (3%) [16–18]. Children developing venous thrombosis
are often carriers for FVL mutation. Unal et al. suggested
that homozygosity for FVL leads to the development of
thrombosis at a young age [19]. Aschka et al. demonstrated
that 26% of children less than 5 years of age and 30% of
children more than 10 years of age with venous thrombosis
and 29% of children with spontaneous venous thrombosis
have harbored FVL mutation [20]. In these series, the
high rate of factor V-Leiden mutation observed among
the tested patients (56.9%) and the tested young adults
(group A) (68.6%) is related to the high prevalence of this
mutation in the Lebanese population. The mutant allele
was highly expressed among Lebanese patients with DVT
and high risk conditions for hypercoagulation states. These
ﬁndings conﬁrm that FVL mutation is a very common risk
factor for venous thrombosis among Lebanese patients and
especially young Lebanese adults with high risk situations,
emphasizing the importance of screening for this mutation
in this particular group of patients.
VTE recurrence rate increases signiﬁcantly in adults and
children when venous thrombosis is associated with primary
hypercoagulopathy and essentially with factor V-Leiden
mutation [21, 22]. More than 66% of the reported patients
with recurrence were carriers for FVL mutation.
FVL mutation, especially in its homozygote form,
increases the risk for venous thrombosis 34-fold among
pregnant women and 35-fold among contraceptive users
[13, 23–25]. FVL mutation has been identiﬁed in 33.3%
of pregnant women and 6.5% of oral contraceptive users
women [26, 27]. In these series, a high percentage of preg-
nant women (66.6%) and of women treated with estrogen
drugs (60%) were carriers for FVL mutation. Screening for
FVLmutationamongLebanesepregnantwomenandamong
women treated with estrogen and presenting for venous
thrombosis is warranted.
A very high incidence of FVL mutation was particularly
detected among patients manifesting resistance to anticoag-
ulants (100%). Testing for FVL among Lebanese patients is
highly recommended when venous thrombosis is extensive
and progressive despite adequate anticoagulation.
FVL mutation interacts with other concurrent acquired
and thrombophilic conditions such as cancer, surgery, long-
haul air travel, and with associated prothrombotic genetic
abnormalities and essentially prothrombin G 20210A muta-
tion to increase the risk of incident venous thrombosis [9,
28–33]. The relative risk for venous thrombosis is calculated
to be 2-3-fold for the prothrombin mutation alone and
20-fold for a combination with FVL mutation [34]. The
three reported patients harboring this combination were
young adults and two of them presented for extensive and
bilateral VTE. FVL acts also as a concurrent risk factor in
individuals with other prothrombotic polymorphism and
hyperhomocysteinemia leading to a synergistic gene-gene
interaction often increasing the risk above the sum of
individual risk factors [35].
In these series, FVL mutation was associated with
MTHFR C 677 T mutation in 9 patients, MTHFR A 1298
C mutation in 8 patients and VH 1299 R mutation in 1
patient. Of the six reported patients carriers for two or
more prothrombotic genetic defects in addition to FVL
mutation and presenting increased homocysteine level, four
patients manifested bilateral extended DVT with pulmonary
embolism resistant to anticoagulants and requiring inferior
vena cava ﬁlter insertion.
Duration of treatment for venous thrombosis among
patients carriers for FVL mutation depends on the nature
and extension of the thrombosis, the underlying risk factors,
the presence of a previous VTE, and the presence and
the severity of concurrent prothrombotic genetic mutation.
Patients homozygotes for FVL mutation and double het-
erozygotes for FVL and prothrombin mutation are consid-
ered for extended long-term treatment with anticoagulants
therapy [36].
5. Conclusion
The high rate of factor V-Leiden mutation observed among
Lebanese patients with lower extremity venous thrombosis
is related to the high prevalence of this mutation among the
Lebanese population. This factor interacts with other con-
current acquired and thrombophilic conditions to increase
the risk of incident venous thrombosis.
The prevalence of FVL mutation is particularly increased
among young patients, pregnant patients, patients treated
with estrogen, patients with recurrent DVT, and patients
with resistance to anticoagulation. The association of two or
moreprothromboticgeneticdefectstoFVLmutationfurther
increases the risks and the severity of venous thrombosis.
Thrombophilia screening should be tailored to accom-
modate a population’s risk factor. In countries with high
prevalence of factor V-Leiden, this mutation should be tested
among patients younger than 50 years even with a transient
risk factor and patients with situations highly suggestive of
hypercoagulation states. This permits to extend the duration
of anticoagulant therapy in high risk patients reducing the
incidenceofpostthromboticsyndromeandrecurrentvenous
thromboembolism.
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